[Progress of treatment of new targets in gastric cancer]
{{output}}
In recent years, biomarkers such as HER-2, PD-L1, and Claudin 18.2 (CLDN 18.2) have provided new opportunities for precision treatment. HER-2-targeted therapies have achieved substantial advancements, while immune checkpoint inhibitors have demonstrated surviv... ...
